The test runs on the BD Viper LT system and detects 14 high-risk types of human papilloma virus.
The firm also announced the appointment of new board members as it heads toward commercialization of a portable MDx platform.
BGI is also developing sequencing-based self-sampling assays for pharmacogenomics and hereditary cancer testing.
The sequencing-based, laboratory-developed test, called SmartJane, contains the first commercially available vaginal microbiome assay.
The test is performed on the company's AmpiProbe platform, and the approval expands Enzo's offering of infectious disease tests in New York.
The group is proposing women ages 30 to 65 be screened with cervical cytology every three years or receive testing for high-risk HPV every five years.
Medcis Pathlabs and its associates and attendees will buy Co-Diagnostics' tests for hepatitis B, hepatitis C, HIV, and human papillomavirus.
The test for cervical cancer screening previously received the IVD mark and US Food and Drug Administration approval on the Cobas 4800 system.
A special issue of Preventive Medicine tackles issues surrounding HPV testing as a primary screening method for cervical cancer in a range of clinical settings.
The test will be developed in Global Good labs and ported onto QuantuMDx's handheld molecular platform.